neovasclar AMD
Conditions
Brief summary
- Number of anti-VEGF injections
Detailed description
- Best-corrected visual acuity (BCVA) assessed by ETDRS Score, - Anatomic changes in the macula assessed with OCT (central retinal thickness, fluid volumes in nl, additional morphologic changes), - Formation of geographic-like macular atrophy assessed by fundus photography with special filters, - Formation of retinal tears assessed by OCT, - Chorioretinal perfusion changes (OCTA), - Perfusion of the neovascular lesion (OCTA, FA), - Changes in macular sensitivity (MP), - Assessment of fibrosis formation and deterioration of the retinal pigment epithelium (PS-OCT), - Quality-of-life assessed by questionnaire
Interventions
DRUGBeovu 120 mg/ml solution for injection in pre-filled syringe
Sponsors
Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Number of anti-VEGF injections | — |
Secondary
| Measure | Time frame |
|---|---|
| - Best-corrected visual acuity (BCVA) assessed by ETDRS Score, - Anatomic changes in the macula assessed with OCT (central retinal thickness, fluid volumes in nl, additional morphologic changes), - Formation of geographic-like macular atrophy assessed by fundus photography with special filters, - Formation of retinal tears assessed by OCT, - Chorioretinal perfusion changes (OCTA), - Perfusion of the neovascular lesion (OCTA, FA), - Changes in macular sensitivity (MP), - Assessment of fibrosis formation and deterioration of the retinal pigment epithelium (PS-OCT), - Quality-of-life assessed by questionnaire | — |
Countries
Austria
Outcome results
None listed